DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The "Atherosclerosis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Atherosclerosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 3, 4, 46, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 20 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

Introduction Atherosclerosis - Overview Atherosclerosis - Therapeutics Development Atherosclerosis - Therapeutics Assessment Atherosclerosis - Companies Involved in Therapeutics Development Atherosclerosis - Drug Profiles Atherosclerosis - Dormant Projects Atherosclerosis - Discontinued Products Atherosclerosis - Product Development Milestones

Companies Featured

Ache Laboratorios Farmaceuticos SA AFFiRiS AG Amgen Inc Annexin Pharmaceuticals AB AstraZeneca Plc Athera Biotechnologies AB Boehringer Ingelheim GmbH Cardax Inc Cerenis Therapeutics Holding SA ChemoCentryx Inc CohBar Inc Daiichi Sankyo Co Ltd DoNatur GmbH Dybly AG Esperion Therapeutics Inc GenKyoTex SA GlaxoSmithKline Plc Immusoft Corp Inotrem SA Inspyr Therapeutics Inc Iproteos SL KineMed Inc Kowa Co Ltd LG Chem Ltd LipimetiX Development Inc MedImmune LLC NuSirt Biopharma Inc Omeros Corp Regeneron Pharmaceuticals Inc Shin Poong PharmCo Ltd The Medicines Company Tolerys SA Vascular Biogenics Ltd Vicore Pharma AB XBiotech Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8xb65v/atherosclerosis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005399/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:52 AM/DISC: 09/14/2018 11:52 AM